

Uniformly curated signaling pathways reveal tissue-specific cross-talks and support drug target discovery

Tamás Korcsmáros^{1,2,†}, Illés J. Farkas^{3,†}, Máté S. Szalay², Petra Rovó¹, Dávid Fazekas¹, Zoltán Spiró², Csaba Böde⁴, Katalin Lenti⁵, Tibor Vellai¹ and Péter Csermely^{2,*}

¹Department of Genetics, Eötvös University, Pázmány P. s. 1C, H-1117 Budapest, ²Department of Medical Chemistry, Semmelweis University, PO Box 260, H-1444 Budapest, ³Statistical and Biological Physics Group of the Hungarian Academy of Sciences, Pázmány P. s. 1A, H-1117 Budapest, ⁴Morgan Stanley Hungary Analytics Ltd., Lechner Ö. f. 8, H-1095 Budapest and ⁵Department of Morphology and Physiology, Semmelweis University, Vas u. 17, H-1088 Budapest, Hungary

Associate Editor: Jonathan Wren

ABSTRACT

Motivation: Signaling pathways control a large variety of cellular processes. However, currently, even within the same database signaling pathways are often curated at different levels of detail. This makes comparative and cross-talk analyses difficult.

Results: We present SignalLink, a database containing eight major signaling pathways from *Caenorhabditis elegans*, *Drosophila melanogaster* and humans. Based on 170 review and ~800 research articles, we have compiled pathways with semi-automatic searches and uniform, well-documented curation rules. We found that in humans any two of the eight pathways can cross-talk. We quantified the possible tissue- and cancer-specific activity of cross-talks and found pathway-specific expression profiles. In addition, we identified 327 proteins relevant for drug target discovery.

Conclusions: We provide a novel resource for comparative and cross-talk analyses of signaling pathways. The identified multi-pathway and tissue-specific cross-talks contribute to the understanding of the signaling complexity in health and disease, and underscore its importance in network-based drug target selection.

Availability: <http://SignalLink.org>

Contact: csermely@eok.sote.hu

Supplementary information: Supplementary data are available at *Bioinformatics* online.

Received on March 1, 2010; revised on April 29, 2010; accepted on June 4, 2010

1 INTRODUCTION

Intracellular signaling, from the simplest cascades to the highly intertwined networks of protein kinases, contributes extensively to the diversity of developmental programs and adaptation responses in metazoans (Pires-daSilva and Sommer, 2003). In humans, defects in intracellular signaling can cause various diseases, e.g. cancer, neurodegeneration or diabetes. Thus, understanding the structure, function and evolution of signal transduction is an important task for both basic research and medicine. By now genetic studies have

uncovered functionally separate, though interacting (cross-talking), pathways and the direction of information flow between pairs of signaling molecules in a number of species (Beyer *et al.*, 2007). On the other hand, biochemical experiments have allowed the detailed characterization of direct physical interactions involved in signaling (Xia *et al.*, 2004). Integrating these data sets using uniform manual curation criteria can significantly contribute to a more precise assessment of their tissue- and cancer-specific utilization and the effects of drug treatments (Davidov *et al.*, 2003). For example, inhibitors used for eliminating a signaling pathway in cancerous cells may in fact have the opposite effect. These drugs may suppress negative feedback loops and thereby, paradoxically, activate the targeted pathway (Sergina *et al.*, 2007).

Intracellular signaling was originally regarded as an assembly of distinct and almost linear cascades. Over the past decade, however, it has been realized that signaling pathways are highly structured and rich in cross-talks (where cross-talk is defined here as a directed physical interaction between pathways). Consequently, intracellular signaling is now viewed as a set of intertwined pathways forming a single signaling network (Papin *et al.*, 2005). This paradigm shift calls for novel experimental, curation and network modeling techniques (Bauer-Mehren *et al.*, 2009).

Currently, high-throughput (HTP) experiments are the major sources of known protein–protein interactions (PPIs). However, so far in most HTP experiments extracellular, membrane-bound and nuclear proteins have been underrepresented. These and other sampling biases strongly reduce their usability for identifying signaling interactions. Another limitation of HTP assays is that they produce undirected interactions even though in signaling directions are essential. Accordingly, several signaling pathway databases have been created recently by manually collecting the directed interactions from the literature (Bauer-Mehren *et al.*, 2009).

Manually curated signaling pathway databases are often assembled without strictly defined and published standardized curation criteria (Lu *et al.*, 2007). Therefore, even within the same database, e.g. in KEGG (Kyoto Encyclopedia of Genes and Genomes; Ogata *et al.*, 1999), the level of detail of curation and the rules for setting pathway boundaries can vary among pathways. In addition, in several signaling resources the definition of signaling pathways has no evolutionary or biochemical background. In other cases, e.g. in Reactome and NetPath (Joshi-Tope *et al.*, 2005;

*To whom correspondence should be addressed.

[†]The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.

Table 1. Comparison of the curation processes of three manually curated databases and Signalink

	KEGG	Reactome	NetPath	Signalink
Source of signaling proteins	Selective manual curation from the literature	Reaction-based manual curation	Selective manual curation from HPRD	Manual curation: pathway-based reviews, experimental papers
Source of interactions	Only reviews	PubMed ID available for each interaction	PubMed ID reaction details for each interaction	PubMed ID listed for each interaction
Number of signaling pathways	10 (no NHR)	10, but not for all species (no Hh, NHR, JAK/STAT)	20 (no WNT, IGF, NHR, JAK/STAT)	8 (EGF/MAPK, WNT, TGF, Notch, IGF, Hh, NHR, JAK/STAT)
Definitions of pathways	Not available	Not available; uniform curation rules	Cancer or immune pathways	Biochemically defined; important in development; uniform curation rules; documented in detail
Pathways in one platform for cross-talk analysis	Not possible	Possible, but no global pathway view or common platform	Not possible	Possible

Only the differences from Signalink are listed. The features setting Signalink most clearly apart have a gray background.

Kandasamy *et al.*, 2010), curation criteria are standardized; however, (i) pathways are usually handled as separate entities; (ii) cross-talks and multi-pathway proteins are underrepresented; and (iii) extracting signaling information from the databases is complicated and labor-intensive, see Section 4 and Supplementary Material for details. Another limitation of several current signaling resources is that they neglect the importance of multi-pathway proteins, i.e. proteins functioning in more than one pathway (Komarova *et al.*, 2005). In summary, the manual curation process needs to be uniform across all pathways and species to aid cross-talk analyses, tests of evolutionary hypotheses, dynamical modeling, setting up predictions and drug target selection (Table 1).

We present Signalink, a signaling resource compiled by applying uniform manual curation rules and data structures across eight major, biochemically defined signaling pathways in three metazoans (Fig. 1). The curation method allowed a systematic comparison of pathway sizes and cross-talks. We found that in humans any two of the eight pathways can cross-talk, and in humans we compared the possible dynamic activities of both the pathways and their cross-talks. We characterized tissue- and cancer-specific expression profiles, and identified proteins relevant for drug target discovery.

2 SYSTEM AND METHODS

2.1 Signaling proteins and interactions

Signalink lists signaling proteins and directed signaling interactions between pairs of proteins in healthy cells of *Caenorhabditis elegans*, *Drosophila melanogaster* and *Homo sapiens*. Each interaction is documented with the PubMed ID of the publication reporting the verifying experiment(s). Signalink was compiled separately for all pathways of the three organisms. Search functions, data and network images of the pathways are available at <http://Signalink.org>.

In each of the three organisms, we first listed signaling proteins and interactions from reviews (and from WormBook in *C.elegans*) and then added further signaling interactions of the listed proteins. To identify additional interactions in *C.elegans*, we examined all interactions (except for transcription regulation) of the signaling proteins listed in WormBase (Rogers *et al.*, 2008) and added only those to Signalink that we could manually identify in the literature as an experimentally verified signaling

interaction. For *D.melanogaster*, we added to Signalink those genetic interactions from FlyBase (Drysdale, 2008) that were also reported in at least one yeast-2-hybrid experiment. For humans, we manually checked the reliability and directions for the PPIs found with the search engines iHop and Chilibot (Chen and Sharp, 2004; Hoffmann and Valencia, 2004).

Signalink assigns proteins to signaling pathways using the full texts of pathway reviews (written by pathway experts). While most signaling resources consider 5–15 reviews per pathway, Signalink uses a total of 170 review papers, i.e. more than 20 per pathway on average. Interactions were curated from a total of 941 articles (PubMed IDs are available at the website). We added a small number of proteins based on InParanoid ortholog clusters (Berglund *et al.*, 2008). For curation, we used a self-developed graphical tool and Perl/Python scripts. The current version of Signalink was completed in May 2008 based on WormBase (version 191), FlyBase (2008.6), Ensembl (49), UniProt (87) and the publications listed on the website. Pathway data can be downloaded in several formats: SQL, CSV, XLS, CYS and SVG exported from Cytoscape and SBML.

2.2 Quality control, database validation and statistical significance tests

The curation protocol of Signalink (Fig. 1A) contains several steps aimed specifically at reducing data and curation errors. We used reviews as a starting point, manually looked up interactions three times, and manually searched for interactions of known signaling proteins with no signaling interactions so far in the database. The section ‘Advantages and limitations of Signalink’ explains validation steps and results in detail. We performed functional significance tests for each of the signaling pathways and their overlaps, i.e. multi-pathway proteins, with the ‘GO Termfinder’ toolbox (Boyle *et al.*, 2004). We found a significant functional similarity between the functions of multi-pathway proteins and the functions of their pathways compared to the control case (functional similarity between the functions of all proteins and all pathways). Moreover, we statistically evaluated the human interactions listed in Signalink with the PRINCESS web service (Li *et al.*, 2008) and found that the ratio of high confidence interactions is 90.6%. Details for all statistical significance tests are available in the Supplementary Material.

2.3 Expression in selected healthy tissues and liver carcinomas

To investigate the dynamic activity of pathway interactions, we selected five healthy tissue types—colorectal, muscle, skin, liver and cardiovascular




Fig. 1. Basic information about SignaLink. (A) The manual curation process. (B) Weighted protein numbers of SignaLink in the eight signaling pathways of the three investigated species. (C) Weighted interaction numbers within pathways and between pathways (cross-talks). See the Supplementary Material for details.

tissues—and two liver carcinomas (Fig. 3, see the details for the selection process of the tissues and controls in the Supplementary Material). Protein expression data in healthy tissue types were downloaded from the eGenetics database (integrated into Ensembl). Protein expression data in two screens of liver carcinomas were obtained from Oncomine 3.6 (Rhodes *et al.*, 2007). We considered a protein differentially expressed if the *P*-value of its expression in at least one of the two screens, as compared to healthy liver tissues and computed by a *t*-test of Oncomine, was below 0.05.

2.4 Functional annotation of drug target candidates

We collected information on the proteins that can be relevant in drug target discovery with DAVID (Database for Annotation, Visualization, and Integrated Discovery; Dennis, Jr. *et al.*, 2003). We downloaded disease-related annotations from OMIM (Online Mendelian Inheritance in Man), genetic association database (GAD) and Orthodisease (Amberger *et al.*, 2009; Becker *et al.*, 2004; O'Brien *et al.*, 2004), domain information from InterPRO (Hunter *et al.*, 2009), and molecular function and cellular component data from Gene Ontology (GO; Harris *et al.*, 2004).

3 RESULTS

3.1 Uniform compilation of signaling pathways in three metazoan species

We curated the signaling pathways of the nematode *C.elegans*, the fruit fly *D.melanogaster*, and *H.sapiens*. From the wide variety of

classification schemes for selecting signaling pathways (Bader *et al.*, 2006), we followed the biochemical approach of Pires-daSilva and Sommer (2003). We selected eight major pathways for curation—EGF/MAPK, Ins/IGF, TGF- β , WNT, Hh (Hedgehog), JAK/STAT, Notch and NHR (Nuclear Hormone Receptors)—that have central roles both in development and in normal cellular signaling.

SignaLink is a manually compiled resource integrating experimentally confirmed genetic and physical interactions from healthy tissue types. Proteins and interactions are listed without tissue-specificity and can be visualized as networks of potential interactions. Tissue- and disease-specific information can be added easily as shown in the examples below. Five combined characteristics create the unique utility of SignaLink.

- (1) Pathways are biochemically defined and encompass all major developmental signaling mechanisms.
- (2) A protein can belong to more than one pathway (if it does, then it is called a multi-pathway protein).
- (3) Proteins are tagged with (i) the pathway(s), (ii) pathway region(s) (core and peripheral) and (iii) the pathway sections (one or two of: ligand, receptor, mediator, co-factor, transcription factor and other) they belong to.
- (4) The level of detail is the same for the entire database.

- (5) Interactions are directed and manually labeled with PubMed IDs (experimental evidence).

Currently, SignalLink lists 560 proteins and 237 interactions from *C.elegans*, 344 proteins and 233 interactions from *D.melanogaster* and 646 proteins with 991 interactions from humans. Similarities and differences between species and pathways are shown in Figures 1B and 1C. The database, its help pages, a detailed description of the curation process, and network visualizations of all pathways are available at <http://SignalLink.org>.

3.2 A large-scale view of species-specific pathway and pathway section sizes

In all three organisms, a few of the eight pathways are central and abundant. Of all proteins, 26–38% participate in the EGF/MAPK and WNT pathways, respectively. Other pathways with high protein numbers are NHR in the worm, Hh and Notch in the fly, and TGF and JAK/STAT in humans. Altogether in each species 68–85% of all signaling proteins participate in these pathways and 56–70% of all cross-talks involve the EGF/MAPK, TGF or WNT pathways. *C.elegans* has almost identical numbers of core and peripheral proteins in each pathway (except for Notch and NHR), while in the other two species the ratio of core to peripheral proteins is around 1.5.

Pathway size differences between the three species are often related to the different environments to which the cells of these organisms have adapted. For example, ligands from the environment can easily reach the nuclei of the worm's cells, thus, the worm's NHR pathway is exceptionally large (58% of all signaling proteins). On the other hand, due to the large variety of signals that human cells are exposed to the human JAK/STAT pathway is oversized compared to the other two species (21% of all signaling proteins in humans versus 0% and 4% in *C.elegans* and *Drosophila*, respectively).

In all three species, EGF/MAPK and IGF have high number of mediators. However, environmental differences may affect pathway section sizes too. In *C.elegans* transcription factors—dominated by the NHR pathway—are the largest pathway section (39%). In the other two species, co-factors by far outnumber other pathway sections (32–42%) and in humans JAK/STAT ligands and receptors are abundant.

3.3 Multi-pathway proteins: proteins functioning in more than one signaling pathway

In *C.elegans*, *D.melanogaster* and humans, we found 6, 12 and 62 multi-pathway proteins, respectively. Within one human signaling pathway the ratio of proteins functioning in at least one other pathway varies from 5% (Notch) to 46% (IGF). Interestingly, a single protein can be even a central (i.e. core) component in more than one pathway. For example, the scaffold protein AXIN and the kinase GSK3 are both core components of more than one signaling pathway (Frame and Cohen, 2001; Luo and Lin, 2004).

We found that EGF/MAPK—the largest pathway—is the only one sharing proteins with all other pathways. On the other end of the spectrum are the Notch, JAK/STAT and NHR pathways: their proteins are contained by three or four other pathways. These differences correlate well with the numbers of pathway functions. Note also that the set of 62 human multi-pathway proteins is enriched with disease-related proteins: 45% (28) of them are known to be




Fig. 2. Maps of signaling cross-talk in three metazoans integrating manually curated data from healthy tissue types. Pathway cores are indicated by darker colors. The width of a link between two pathways is proportional to the (weighted) number of directed signaling interactions (cross-talks) between the two pathways. A directed signaling interaction between two proteins annotated to n and m pathways, respectively, adds $1/(nm)$ to the weight between any two of the directed pathway pairs connected by this interaction. Two oppositely directed interactions are counted separately. (A–C) Cross-talks, i.e. signaling interactions between pathways. Note that in humans any two pathways can cross-talk. (D–F) Cross-talk by pathway sections. In humans, cross-talk is ubiquitous even among pathway sections, while in the other two species mostly co-factors and mediators cross-talk. See Methods for details and <http://SignalLink.org> for datasets.

disease-related, while in the eight human signaling pathways only 25.5% (165 of 646) and among all human proteins listed by Ensembl only 20% (3929 of 19 534). For both comparisons $P < 0.001$.

3.4 Cross-species comparison of cross-talks

Next, we focused on how the complexity of intracellular signaling increases with a growing complexity of the organisms. In *C.elegans* only six of the eight curated pathways are active, and the Notch pathway is isolated (Fig. 2A). In addition, the cross-talk network of the pathways—where nodes represent pathways and links represent cross-talks—is sparse. Between the six active pathways only 5 of

the 30 (= 6 × 5) possible cross-talk types are present. In *Drosophila*, all eight curated pathways of SignalLink are active, but the NHR and JAK/STAT pathways are still isolated. Without these two pathways, the cross-talk network is already significantly denser than in the worm: 16 of the total 30 possible cross-talk types are present (Fig. 2B). In humans (the most complex organism of the three), all eight curated signaling pathways are active and almost all of the 56 possible cross-talk types are possible (Fig. 2C). The ubiquity of cross-talks (all 28 pathway pairs can cross-talk) expands both the repertoire of possible phenotypes and the system-level responses to environmental and pathological changes.

In *C.elegans* cross-talk is possible through receptors, mediators and transcription factors (Fig. 2D). In the other two species, all pathway sections can participate in cross-talk, except for the NHR and JAK/STAT pathways of *Drosophila*, where cross-talk occurs mostly at the transcriptional level and through mediators, respectively (Fig. 2E and F).

In addition to the number of active pathways and cross-talks, a further important indicator of signaling complexity is the number of cross-talks relative to all signaling interactions. In the worm 4.6% of all signaling interactions are cross-talks, in the fly 10.5% and in humans 30.3%. Interestingly, the growth of the number of cross-talks from worm to fly and human is not simply due to the growth of the number of protein-coding genes (20 100, 13 800 and 23 000, respectively) or the number of signaling-related PubMed articles (3889, 11 367 and 214 193 in worms, flies and humans, respectively).

The presence of cross-talks in many pathways and pathway sections is a sign of the efficient utilization of resources: expanding the functions of an already existing pathway protein is more efficient than evolving a novel protein (Bhattacharyya *et al.*, 2006). Given the high number of signaling cross-talks, a large variety of specific and robust phenotypes may emerge (Taniguchi *et al.*, 2006). However, the actual signaling responses are controlled mainly by scaffold proteins, feedback loops, kinetic insulation, and the spatial and temporal expression patterns of proteins (Behar *et al.*, 2007; Bhattacharyya *et al.*, 2006; Freeman, 2000; Kholodenko, 2006). To map some of these possibilities, we investigated the dynamical activity of signaling cross-talks in humans where cross-talk was found ubiquitous.

3.5 Tissue- and disease-specific activity of cross-talks

Cross-talks, similar to other PPIs, are not active permanently in all tissue types. We considered an interaction to be possibly active in a given tissue type, if both of the mRNAs of its participating proteins are expressed in that tissue. It is reasonable to assume (as a simple approximation) that proteins whose mRNAs are expressed could be active in the given tissue (compared to those that are not transcribed). After merging SignalLink with protein expression profiles from human colorectal, muscle, skin, liver and cardiovascular tissues, we quantified the possible tissue-specific activity of cross-talks. We found that cross-talks between the pathways EGF/MAPK and TGF, and cross-talks from WNT to TGF and from EGF/MAPK to JAK/STAT are overrepresented (Wald-test, upper limit: 7.25%) The complete statistical test is available in the Supplementary Material. In addition, we found that (i) the Notch and NHR pathways are the least connected to other pathways and (ii) Notch and JAK/STAT are the least and most frequently used pathways, respectively: on




Fig. 3. Possible dynamical activity of the signaling interactions between and within pathways in (A) five selected healthy human tissue types and (B) two human liver carcinomas. (A) In the selected healthy tissue types, the pathways EGF/MAPK, WNT, TGF and IGF have the potential to cross-talk most frequently, while the cross-talk connections of the Notch pathway have less potential to be active. (B) In the two investigated liver carcinomas signaling interactions within the EGF/MAPK, WNT, and TGF pathways and their cross-talks are most extensively changed, while the cross-talks of the Notch pathway are the least affected. See text for details.

average 26% and 48% of their proteins are expressed in the selected healthy tissue types (Fig. 3A).

Cancers are often viewed as systems diseases (Hornberg *et al.*, 2006). In cancer cells large-scale modifications of signaling pathways, especially changes of cross-talks (Stelling *et al.*, 2004), are prevalent. Accordingly, detecting which proteins (cross-talks) are differentially expressed (active) in a carcinoma tissue may point out key causes of the given tumour and can help the identification of novel, systems-based drug targets (Korcsmaros *et al.*, 2007; Tortora *et al.*, 2004). To do this, we merged the network of eight human signaling pathways with protein expression data from human liver carcinomas. We considered a signaling interaction to be altered in these two liver carcinomas, if, compared to healthy liver tissues, at

least one of the participating proteins was differentially expressed (see Section 2 for details). In three of the eight pathways (WNT, NHR and JAK/STAT) only ~30% of all proteins were differentially expressed in the investigated liver carcinomas, while in the other five pathways this ratio was ~50% (Fig. 3B).

In summary, the largest signaling pathway, EGF/MAPK, is frequently used in the selected tissue types and significantly changed in the two liver carcinomas. JAK/STAT is also strongly used, but less modified in the two investigated liver carcinomas. A third example is Notch, which is neither strongly used nor strongly modified. Thus, even though cross-talks are possible between all pairs of investigated human signaling pathways, the possible activity of these pathways in healthy tissues and the modifications of their cross-talks in the analyzed cancer types are highly diverse. See the Supplementary Material for additional literature support.

3.6 Potential role of cross-talking proteins in drug target discovery

Signaling proteins are overrepresented among human disease genes (Sakharkar *et al.*, 2007) and are intensively studied as potential drug target candidates (Chaudhuri and Chant, 2005), often with network-based methods (Berger and Iyengar, 2009). Among the 62 human multi-pathway proteins, 21 (33.8%) are known drug targets compared to 15% (94 of 646) in all 8 pathways and 8.2% (1610 of 19534) among all human proteins. This implies that the remaining set of 41 human multi-pathway proteins may also be relevant for drug target discovery. In summary, the following two sets, altogether 327 proteins in our current study, are likely to be enriched with possible drug targets: (i) human multi-pathway proteins and (ii) proteins participating in cancer-related cross-talks.

We analyzed the drug target relevance of human signaling proteins by examining four key properties: disease-relatedness, localization in the plasma membrane (Gao *et al.*, 2008; Yildirim *et al.*, 2007), enzymatic functions and kinase domain content (Fabbro *et al.*, 2002). To identify the most promising drug target candidates from the 327 proteins selected in the previous paragraph, we first listed those nine that have all four key properties, i.e. disease-related enzymes (with a kinase domain) localized in the membrane (Fig. 4). Out of these nine proteins five (CASK, EGFR, ErbB2, IGF1R, and INSR) are currently used as drug targets, while the other four (IRAK1, MAP3K13/LZK/MLK, ROR2 and TGFBR1) are not. ROR2 is essential during bone formation (Liu *et al.*, 2007) and the other three proteins are inflammation-related factors (Klein *et al.*, 2001). Interestingly, ROR2 was recently suggested as a therapeutic target for osteosarcoma based on expression analysis and siRNA treatment (Morioka *et al.*, 2009). As for IRAK1, TGFBR1 and MLK, anti-inflammatory drugs (imiquimod, dexamethasone and L-arginine, respectively) frequently affect their pathways, but without sufficient specificity (Klein *et al.*, 2001). These findings support our predictions that these four human signaling proteins are promising novel drug targets.

4 DISCUSSION

4.1 Advantages and limitations of SignaLink

According to a recent study (Cusick *et al.*, 2009), manual curation projects: (i) inherit the selection biases of the curated experiments; (ii) often lack the specific goals clearly defining the curation




Fig. 4. Analysis of drug target candidate proteins listed with SignaLink. (A) The numbers of membrane proteins (m), enzymes (e), proteins with kinase domains (k) and disease-related proteins (d) among the three groups of proteins listed in SignaLink as possible novel drug targets (control: all SignaLink proteins). (B) Proteins with a fixed number of key properties out of the listed four (m, e, k and d). For each group the number of drug target proteins is shown separately. The names of the most promising candidates (have all four properties, not yet targeted) are listed.

criteria; and (iii) it is usually difficult to estimate their completeness and reliability. Note, however, that many signaling proteins function outside the cell (ligands), in membrane-bound positions (receptors), or in the nucleus (transcription factors), and that proteins from these compartments are underrepresented in current HTP data. Thus, for the purpose of identifying signaling proteins and interactions HTP techniques seem to be less adequate than those manual curation projects that have clear goals. In the case of SignaLink, the precisely defined curation process combines original research articles and reviews, thus, both experimental evidence and its critical discussion by specialists are included.

Applying a biochemically based, well-documented and clear pathway definition is central to SignaLink. For example, the EGF/MAPK pathway in SignaLink contains (with evolutionary and biochemical reasoning) the pathway from the EGF ligand to the terminal MAPK kinases. In several other databases, this pathway is scattered across many separate (sub)pathways (e.g. EGFR, RAS, p38, JNK, ERK and ASK). An important consequence of precise pathway definitions is the reduced number of examined pathways. We suggest that appropriate and precise grouping, avoiding artificial pathway constructs, may be a better indicator of the goodness of the resource than merely the large number of pathways.

Table 2. Comparison of database content for human pathways between three manually curated databases and Signalink

	KEGG	Reactome	NetPath	Signalink
Pathways	MAPK, Insulin, Hedgehog, JAK/STAT, Notch, TGF-β, WNT	EGFR, Insulin receptor, Notch, TGF, WNT	EGFR1, Hedgehog, Notch, TGF, WNT	EGF/MAPK, IGF, Hh, JAK/STAT, Notch, NHR, TGF, WNT
Number of proteins and interactions ^a				
Proteins	429 (483)	56 ^b (348)	362 (355)	646 ^c
Interactions	1502 ^d (990)	682 ^b (689)	457 (701)	991
<i>cross-talks</i>	225 ^d (228)	79 ^b (226)	60 (171)	300 ^e
Number of publications ^a	73	166	351	941

In each pairwise comparison, we compared only the pathways curated in both databases. In KEGG, only protein complexes and their interactions were available and we constructed a list of binary interactions, i.e. a network, with the 'matrix' method (Bader and Hogue, 2002).
^aFor the same pathways in Signalink: EGFR, EGFR1 and MAPK are compared to the EGF/MAPK pathway of Signalink.
^bBinary interactions from membership in the same complex.
^cIncluding predicted pathway member proteins.
^dFor each directed interaction between two protein groups (KEGG complexes), we added a directed link between each protein of the source group and each protein of the target group.
^eWeighted cross-talk interaction number: a directed signaling interaction between two proteins annotated to *n* and *m* pathways, respectively, adds 1/(*nm*) to the weight between any two of the directed pathway pairs connected by this interaction. See the Supplementary Material for further details.
Cross-talks (in italics) are a subgroup of all interactions.

Of the constantly increasing number of signaling databases (Bader *et al.*, 2006) many are proprietary, list fewer than 200 molecules, or only selected types of pathway components, e.g. protein kinases. Even among the few databases passing these criteria (free for academic use, more than 200 molecules, all pathway component types included) there are currently no gold standards compiled with similar goals and methods as Signalink. It is, therefore, important to compare both the curation protocols and the actual data of several available databases before selecting one of them for a particular analysis. In Table 2, we compare three widely used pathway databases—KEGG, Reactome, and NetPath—and Signalink (see the Supplementary Material for details). In each pairwise comparison, we used the pathways available in both databases.

According to Table 2 and the Supplementary Material, Signalink has the following advantages compared to the three analyzed databases: (i) precisely defined and documented curation protocol; (ii) highest numbers of signaling proteins and interactions in the curated signaling pathways; (iii) highest numbers of cross-talks and multi-pathway proteins; (iv) largest protein overlap with the other databases; (v) a higher than average number of publications used per pathway; (vi) minimal usage of protein isoform names; (vii) no binary interactions inferred from the membership of two proteins in the same complex; (viii) low number of proteins from UniProt/TrEMBL (i.e., few unverified proteins). Signalink was compiled based on pathway reviews and primary research articles. Thus, the high numbers of signaling proteins (including multi-pathway proteins) and cross-talks are likely to be dominated by true positives, indicating higher precision and coverage.

Despite the care we have taken in creating Signalink, it does have limitations, e.g., Signalink does not contain all signaling proteins. Only those signaling proteins have been included that have an experimentally verified function in the selected eight major pathways or a directed interaction with at least one of their proteins. Several groups of proteins were fully excluded from Signalink. These groups, together with our detailed reasons for excluding them, are listed in the Supplementary Material. The compilation

of Signalink was based on published review and research papers. Note that the curation of the current version of Signalink was closed in May 2008. Naturally, more pathways (defined by the same evolutionary and biochemical rules) and proteins can be added in a future version. We plan to update Signalink every July (starting 2011). The next update will include recent high-confidence HTP data. Overall, based on the comparison we presented in this subsection, we expect that the limitations of Signalink are small compared to the improvements it can provide.

4.2 Current applications

The primary goal of Signalink is to provide *maps of global pathway communication* in three metazoans (*C.elegans*, *D.melanogaster* and *H.sapiens*) with well-documented, uniform manual curation. Interactions from all healthy tissue types were included into Signalink, and expression data from selected tissues were used for dynamic analysis. We found that the pathways EGF/MAPK, JAK/STAT and Notch are clear examples for three distinct types of behavior: (i) high expression in normal tissue types and strong changes in cancer; (ii) high expression, but small changes; and (iii) low expression and small changes. See the Supplementary Material for additional literature support.

Network analyses—combined with system-level resources—can contribute to modern *drug target discovery*, e.g. to polypharmacology and multi-target drug selection (Hopkins, 2008; Korcsmaros *et al.*, 2007). With Signalink, one can prioritize novel drug target candidates by examining the list of: (i) multi-pathway proteins and (ii) proteins participating in cancer-related cross-talks. Some of these proteins could be specific and proper targets, some of them could be too central and aspecific. After listing the properties of these proteins relevant for drug target selection, we suggested four novel drug target candidates. One of them, ROR2, was recently proposed as a novel chemotherapeutic target, while the other three are known to be non-specifically affected by anti-inflammatory drugs. A broader list contains 35 additional proteins with a lower confidence, which may be again filtered with additional criteria, e.g. phosphatase activity.

In biomedical experimental work, the functions of a few selected proteins are often modified. These changes can unexpectedly perturb signaling pathways and non-specifically affect cellular processes. Based on several data sources, including Signalink, we have launched a web server, PathwayLinker, to aid experimental work by linking the queried proteins to signaling pathways through physical and/or genetic interactions (Farkas *et al.*, submitted for publication).

4.3 Future applications

As their name suggests, targeting multi-pathway proteins may not be selective. However, selectivity is a key property in pharmacology, thus, analyses of multi-pathway proteins could support drug target discovery. Based on Signalink, we suggest single-gene knock-out experiments or RNA silencing of individual cross-talking proteins to help understand the *functional selectivity* of signaling pathways and to reduce the redundancies that are assumed to make many currently used drugs less efficient (Tortora *et al.*, 2004; Urban *et al.*, 2007).

For the *mathematical modeling* of the dynamical behavior of biomolecular pathways the precise, high-coverage reconstruction of the static network structure of these pathways is crucial (Papin *et al.*, 2005). In the case of signaling pathways, the manual curation of the existing literature can be efficient for assembling large-scale interaction maps. Signalink datasets have a simple and uniform structure and are available in several formats for all eight pathways and three species at <http://Signalink.org>. This allows one to easily merge Signalink with stoichiometric and expression data from, e.g. perturbation analyses (Papin *et al.*, 2005). The static network provided by Signalink can serve as a backbone for both numerical and differential equation-based models and—due to Signalink's focus on cross-talks—for deciphering the rules of cooperation between pathways (Borisov *et al.*, 2009; Wang *et al.*, 2009). Finally, perturbation analyses that cannot be carried out with HTP PPI networks (they list undirected PPIs), may be manageable with Signalink, because it contains the directions of interactions.

A central goal of *synthetic biology* is to engineer cells that can carry out novel tasks (Bhattacharyya *et al.*, 2006; Friedland *et al.*, 2009). One way to achieve this goal is to rewire signaling circuits by modifying scaffold proteins and other biomolecules or by changing feed-back loops. In these studies, detailed high-quality maps of intracellular signaling are essential, especially the positions of cross-talks and multi-pathway proteins.

Comparative evolutionary studies usually focus on conserved and altered mechanisms underlying the observed differences in body plans. Among metazoans, these differences are largely due to changes in the complexity of regulation rather than different gene numbers (Levine and Tjian, 2003; Szathmari *et al.*, 2001). Two decisive regulatory networks in this case are transcriptional control and signaling, in particular, cross-talks. Signalink was compiled with uniform curation rules for eight major pathways in three metazoans that have similar signaling mechanisms but different morphologies. Therefore, the datasets of Signalink are well applicable to studying evolutionary changes.

5 CONCLUSIONS

Contrary to earlier views, signaling pathways are now understood as interlinked (not linear) routes heavily interlinked by cross-talks. This major paradigm shift necessitates novel, systems-based approaches,

e.g. new techniques for curation and modeling. Attempting to meet the novel curation requirements, we have compiled a signaling pathway resource, Signalink. It allows the systematic comparison of pathways and their cross-talks. After finding that any two of the eight selected human signaling pathways may cross-talk, we quantified the possible activity patterns of these cross-talks in healthy and cancerous human tissues. Large-scale mapping of pathways and the activity patterns of their cross-talks revealed multi-pathway and cancer-related cross-talking proteins that can be relevant for drug target discovery.

ACKNOWLEDGEMENTS

We thank B. Papp, F. Jordan, and L. Zsakai for comments; P. Connolly for proofreading; T. Vicsek for discussions; G. Szuromi, R. Palotai, and P. Pollner for technical help. The authors are grateful to the anonymous referees for their comments and suggestions.

Funding: EU 6th Framework Programme (FP6-518230); Hungarian National Science Fund (OTKA K69105, K75334, K68669); Hungarian National Office for Research and Technology (CellCom RET); EEA Fellowship (to I.J.F.).

Conflict of Interest: none declared.

REFERENCES

- Amberger, J. *et al.* (2009) McKusick's Online Mendelian Inheritance in Man (OMIM). *Nucleic Acids Res.*, **37**, D793–D796.
- Bader, G.D. *et al.* (2006) Pathguide: a pathway resource list. *Nucleic Acids Res.*, **34**, D504–D506.
- Bader, G.D. and Hogue, C.W. (2002) Analyzing yeast protein-protein interaction data obtained from different sources. *Nat. Biotechnol.*, **20**, 991–997.
- Bauer-Mehren, A. *et al.* (2009) Pathway databases and tools for their exploitation: benefits, current limitations and challenges. *Mol. Syst. Biol.*, **5**, 290.
- Becker, K.G. *et al.* (2004) The genetic association database. *Nat. Genet.*, **36**, 431–432.
- Behar, M. *et al.* (2007) Kinetic insulation as an effective mechanism for achieving pathway specificity in intracellular signaling networks. *Proc. Natl Acad. Sci. USA*, **104**, 16146–16151.
- Berger, S.I. and Iyengar, R. (2009) Network analyses in systems pharmacology. *Bioinformatics*, **25**, 2466–2472.
- Berglund, A.C. *et al.* (2008) InParanoid 6: eukaryotic ortholog clusters with inparalogs. *Nucleic Acids Res.*, **36**, D263–D266.
- Beyer, A. *et al.* (2007) Integrating physical and genetic maps: from genomes to interaction networks. *Nat. Rev. Genet.*, **8**, 699–710.
- Bhattacharyya, R.P. *et al.* (2006) Domains, motifs, and scaffolds: the role of modular interactions in the evolution and wiring of cell signaling circuits. *Annu. Rev. Biochem.*, **75**, 655–680.
- Borisov, N. *et al.* (2009) Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. *Mol. Syst. Biol.*, **5**, 256.
- Boyle, E.I. *et al.* (2004) GO TermFinder—pen source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. *Bioinformatics*, **20**, 3710–3715.
- Chaudhuri, A. and Chant, J. (2005) Protein-interaction mapping in search of effective drug targets. *Bioessays*, **27**, 958–969.
- Chen, H. and Sharp, B.M. (2004) Content-rich biological network constructed by mining PubMed abstracts. *BMC Bioinformatics*, **5**, 147.
- Cusick, M.E. *et al.* (2009) Literature-curated protein interaction datasets. *Nat. Methods*, **6**, 39–46.
- Davidov, E. *et al.* (2003) Advancing drug discovery through systems biology. *Drug Discov. Today*, **8**, 175–183.
- Dennis, G., Jr. *et al.* (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. *Genome Biol.*, **4**, 3.
- Drysdale, R. (2008) FlyBase: a database for the *Drosophila* research community. *Methods Mol. Biol.*, **420**, 45–59.
- Fabbro, D. *et al.* (2002) Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. *Pharmacol. Ther.*, **93**, 79–98.

- Frame,S. and Cohen,P. (2001) GSK3 takes centre stage more than 20 years after its discovery. *Biochem. J.*, **359**, 1–16.
- Freeman,M. (2000) Feedback control of intercellular signalling in development. *Nature*, **408**, 313–319.
- Friedland,A.E. et al. (2009) Synthetic gene networks that count. *Science*, **324**, 1199–1202.
- Gao,Z. et al. (2008) PDPTD: a web-accessible protein database for drug target identification. *BMC Bioinformatics*, **9**, 104.
- Harris,M.A. et al. (2004) The Gene Ontology (GO) database and informatics resource. *Nucleic Acids Res.*, **32**, D258–D261.
- Hoffmann,R. and Valencia,A. (2004) A gene network for navigating the literature. *Nat. Genet.*, **36**, 664.
- Hopkins,A.L. (2008) Network pharmacology: the next paradigm in drug discovery. *Nat. Chem. Biol.*, **4**, 682–690.
- Hornberg,J.J. et al. (2006) Cancer: a systems biology disease. *Biosystems*, **83**, 81–90.
- Hunter,S. et al. (2009) InterPro: the integrative protein signature database. *Nucleic Acids Res.*, **37**, D211–D215.
- Joshi-Tope,G. et al. (2005) Reactome: a knowledgebase of biological pathways. *Nucleic Acids Res.*, **33**, D428–D432.
- Kandasamy,K. et al. (2010) NetPath: a public resource of curated signal transduction pathways. *Genome Biol.*, **11**, R3.
- Kholodenko,B.N. (2006) Cell-signalling dynamics in time and space. *Nat. Rev. Mol. Cell Biol.*, **7**, 165–176.
- Klein,T.E. et al. (2001) Integrating genotype and phenotype information: an overview of the PharmGKB project. *Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J.*, **1**, 167–170.
- Komarova,N.L. et al. (2005) A theoretical framework for specificity in cell signaling. *Mol. Syst. Biol.*, **1**, 2005.
- Korcsmaros,T. et al. (2007) How to design multi-target drugs: target-search options in cellular networks. *Expert Opin. Drug Discov.*, **2**, 799–808.
- Levine,M. and Tjian,R. (2003) Transcription regulation and animal diversity. *Nature*, **424**, 147–151.
- Li,D. et al. (2008) PRINCESS, a protein interaction confidence evaluation system with multiple data sources. *Mol. Cell. Proteomics*, **7**, 1043–1052.
- Liu,Y. et al. (2007) Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-3(beta) phosphorylation and promotes osteoblast differentiation and bone formation. *Mol. Endocrinol.*, **21**, 3050–3061.
- Lu,L.J. et al. (2007) Comparing classical pathways and modern networks: towards the development of an edge ontology. *Trends Biochem. Sci.*, **32**, 320–331.
- Luo,W. and Lin,S.C. (2004) AXIN: a master scaffold for multiple signaling pathways. *Neurosignals*, **13**, 99–113.
- Morioka,K. et al. (2009) Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. *Cancer Sci.*, **100**, 1227–1233.
- O'Brien,K.P. et al. (2004) OrthoDisease: a database of human disease orthologs. *Hum. Mutat.*, **24**, 112–119.
- Ogata,H. et al. (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res.*, **27**, 29–34.
- Papin,J.A. et al. (2005) Reconstruction of cellular signalling networks and analysis of their properties. *Nat. Rev. Mol. Cell Biol.*, **6**, 99–111.
- Pires-daSilva,A. and Sommer,R.J. (2003) The evolution of signalling pathways in animal development. *Nat. Rev. Genet.*, **4**, 39–49.
- Rhodes,D.R. et al. (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. *Neoplasia*, **9**, 166–180.
- Rogers,A. et al. (2008) WormBase 2007. *Nucleic Acids Res.*, **36**, D612–D617.
- Sakharkar,M.K. et al. (2007) Druggability of human disease genes. *Int. J. Biochem. Cell Biol.*, **39**, 1156–1164.
- Sergina,N.V. et al. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. *Nature*, **445**, 437–441.
- Stelling,J. et al. (2004) Robustness of cellular functions. *Cell*, **118**, 675–685.
- Szathmari,E. et al. (2001) Molecular biology and evolution. Can genes explain biological complexity? *Science*, **292**, 1315–1316.
- Taniguchi,C.M. et al. (2006) Critical nodes in signalling pathways: insights into insulin action. *Nat. Rev. Mol. Cell Biol.*, **7**, 85–96.
- Tortora,G. et al. (2004) Strategies for multiple signalling inhibition. *J. Chemother.*, **16** (Suppl. 4), 41–43.
- Urban,J.D. et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. *J. Pharmacol. Exp. Ther.*, **320**, 1–13.
- Wang,C.C. et al. (2009) PI3K-dependent cross-talk interactions converge with Ras as quantifiable inputs integrated by Erk. *Mol. Syst. Biol.*, **5**, 246.
- Xia,Y. et al. (2004) Analyzing cellular biochemistry in terms of molecular networks. *Annu. Rev. Biochem.*, **73**, 1051–1087.
- Yildirim,M.A. et al. (2007) Drug-target network. *Nat. Biotechnol.*, **25**, 1119–1126.